Development and validation of LC-MS/MS for bioanalysis of hydroxychloroquine in human whole blood

서지정보

ㆍ발행기관 : 충북대학교 동물의학연구소 ㆍ수록지정보 : Journal of Biomedical and Translational Research / 19권 / 4호
ㆍ저자명 : Jung Youl Park, Hyun Ho Song, Young Ee Kwon, Seo Jin Kim, Sukil Jang, Seong Soo Joo

목차

Introduction
Materials and Methods
Chemicals and reagents
Pharmaceutical formulation
LC-MS and LC-MS/MS analyses
Standard curve and sample preparation
Validation
Precision, accuracy and recovery
Matrix effect
Stability experiments
Parallel bioequivalence study and statistical analysis
Results and Discussion
Optimization of sample preparation and chromatographicconditions
Method validation
Stability verification
Application of parallel design to a bioequivalence study
References

영어 초록

This study aimed to analyze a high-performance liquid chromatography (HPLC) separation using a pentafluorophenyl column of parent drug hydroxychloroquine (HCQ) and its active metabolite, desethylhydroxchloroquine (DHCQ) applying to determine bioequivalence of two different formulations administered to patients. A rapid, simple, sensitive and specific liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been developed and validated for bioanalysis of HCQ and its metabolite DHCQ in human whole blood using deuterium derivative hydroxychloroquine-D4 as an internal standard (IS). A triple-quadrupole mass spectrometer was operated using electrospray ionization in multiple reaction monitoring (MRM) mode. Sample preparation involves a two-step precipitation of protein techniques. The removed protein blood samples were chromatographed on a pentafluorophenyl (PFP) column (50 mm × 4.6 mm, 2.6 μm) with a mobile phase (ammonium formate solution containing dilute formic acid) in an isocratic mode at a flow rate of 0.45 mL/min. The standard curves were found to be linear in the range of 2 – 500 ng/mL for HCQ; 2 – 2,000 ng/mL for DHCQ in spite of lacking a highly sensitive MS spectrometry system. Results of intra- and inter-day precision and accuracy were within acceptable limits. A run time of 2.2 min for HCQ and 2.03 min for DHCQ in blood sample facilitated the analysis of more than 300 human whole blood samples per day. Taken together, we concluded that the assay developed herein represents a highly qualified technology for the quantification of HCQ in human whole blood for a parallel design bioequivalence study in a healthy male.

참고 자료

없음